Neonatal immunization with pneumococcal conjugate vaccine in Papua New Guinea

巴布亚新几内亚新生儿接种肺炎球菌结合疫苗

• 批准号: nhmrc : 303123
• 负责人: A/Pr Deborah Lehmann
• 金额: $ 78.81万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/neonatal-immunization-pneumococcal-new-guinea/83077
• 关键词: Neonatal; immunization; pneumococcal; conjugate; vaccine

One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries; transfer state-of-the-art immunological technology and stimulate further collaborations on respiratory infections in the region.

每年有100万儿童死于肺炎球菌病，其中大多数在第三世界。许多人在婴儿早期死亡，婴儿出生时可能会受益于Pnc结合疫苗（PnarTM）的免疫接种。巴布亚新几内亚医学研究中心、Telethon儿童健康研究所和西澳大利亚大学儿科系将合作密切审查这种方法的安全性，特别是对婴儿免疫力发展和对其他疫苗反应的影响。这项研究还将为两国的巴布亚新几内亚和澳大利亚科学家提供一个独特的培训机会;转让最先进的免疫技术，并促进该地区在呼吸道感染方面的进一步合作。